Changes in lipid biomarkers, liver stiffness and steatosis following sodium-glucose cotransporter two inhibitor therapy in type two diabetes

doi:10.4254/wjh.125505

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 10

This Article

(4)

(6)

(0)

(39)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Hepatol. Oct 27, 2026; 18(10): 125505
Published online Oct 27, 2026. doi: 10.4254/wjh.125505

Table 8 Comparison of selected laboratory parameters across advanced fibrosis risk categories defined by the nonalcoholic fatty liver disease fibrosis score and Fibrosis-4 index after 6 months of sodium-glucose cotransporter 2 inhibitor therapy

Parameter	Low risk	Intermediate risk	High risk	P value¹
NFS	n = 9	n = 41	n = 15
ALT (U/L)	38 (33.5-84)	35 (29.5-59)	28 (19.5-35.5)	0.01^a
AST (U/L)	34 (24.5-54)	26 (23.5-40.5)	23 (18-28)	0.18
AST/ALT ratio	0.7 (0.6-0.9)	0.7 (0.7-0.9)	0.9 (0.7-1.1)	< 0.001^b
Erythrocytes	4.8 (4.6-5.3)	5.3 (4.9-5.8)	4.9 (4.4-5.1)	0.01^c
MCV (fL)	84.5 (82.6-92.7)	84.7 (81.7-87.4)	88 (85.8-92)	0.04^a
Platelet count (10⁹/L)	282 (264.5-355.5)	318 (277.5-391)	240 (207-260.5)	< 0.001^b
Leukocytes (10⁹/L)	9.4 (7.4-10)	9.2 (6.9-10.6)	7.8 (6.6-9.1)	0.20
Albumin (g/L)	44.7 (44-46.3)	45.3 (44.1-48.7)	45 (43.4-47)	0.04^d
Total protein (g/L)	74 (70-77.5)	77 (74-78)	72 (69-74.8)	0.02^a
FIB-4	n = 52	n = 11	n = 4
ALT (U/L)	26 (20.3-35)	21 (17-29)	22.5 (15-38.3)	0.44
AST (U/L)	23.5 (20-28)	23 (21-31)	34 (22-44.5)	0.30
AST/ALT ratio	0.9 (0.7-1.1)	1.2 (0.7-1.4)	1.3 (1.2-1.7)	0.004^a
Erythrocytes	5 (4.6-5.4)	5 (4.7-5.5)	4.3 (4.1-5)	0.15
MCV (fL)	88 (84.7-91.3)	88 (85.9-91.5)	88 (85.6-88.9)	0.90
Platelet count (10⁹/L)	248 (214-283)	193 (174-221)	145.5 (139.3-177.3)	< 0.001^a
Leukocytes (10⁹/L)	8.3 (7.3-9.5)	7.6 (6.9-9.8)	5.5 (4.7-6)	0.01^d
Albumin (g/L)	45.3 (43.1-47)	47.4 (43.1-47.7)	44.4 (41.3-46.2)	0.47
Total protein (g/L)	74 (70.4-77)	76 (71-77)	70 (70-72.3)	0.24

¹Kruskal-Wallis test (post hoc Conover test).

^aP < 0.05 were observed between the low-risk group and the intermediate- and high-risk groups.

^bP < 0.05 were observed between all three risk groups.

^cP < 0.05 were observed between the low- and high-risk groups.

^dP < 0.05 were observed between the high-risk group and the low- and intermediate-risk groups.

n denotes the number of patients in each fibrosis risk category. Values are presented as median (interquartile range). ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; MCV: Mean corpuscular volume; NFS: Nonalcoholic fatty liver disease fibrosis score; FIB-4: Fibrosis-4 index.

Full Size Table

Citation: Khaznadar F, Bojanić K, Khaznadar O, Jurić A, Hefer M, Kralik K, Petrović A, Hrženjak A, Lončar A, Steiner J, Smolić M, Smolić R. Changes in lipid biomarkers, liver stiffness and steatosis following sodium-glucose cotransporter two inhibitor therapy in type two diabetes. World J Hepatol 2026; 18(10): 125505
URL: https://www.wjgnet.com/1948-5182/full/v18/i10/125505.htm
DOI: https://dx.doi.org/10.4254/wjh.125505

Khaznadar F, Bojanić K, Khaznadar O, Jurić A, Hefer M, Kralik K, Petrović A, Hrženjak A, Lončar A, Steiner J, Smolić M, Smolić R. Changes in lipid biomarkers, liver stiffness and steatosis following sodium-glucose cotransporter two inhibitor therapy in type two diabetes. World J Hepatol 2026; 18(10): 125505 [DOI: 10.4254/wjh.125505]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.